Santaris Pharma pockets $48.3M in VC

Denmark's Santaris Pharma has raised $48.3 million in venture funds. ABN AMRO Capital Life Sciences of the Netherlands led the round. Santaris has specialized in developing RNA Antagonist drugs based on Locked Nucleic Acid.

- here's the release

PLUS: Helicos BioSciences, which specializes in high-speed, high-sensitivity DNA sequencing, has garnered $40 million in new venture funds. The financing was provided by Helicos BioSciences' current investors, which includes Flagship Ventures, Atlas Ventures, Highland Capital, MPM Capital, and Versant Ventures. Release

ALSO: BioXell has added €10.5 million to its third round of venture capital. TVM Capital led the financing. Release